<DOC>
	<DOCNO>NCT01253070</DOCNO>
	<brief_summary>This phase II trial study well sorafenib tosylate chemotherapy work treat old patient acute myeloid leukemia ( AML ) . Sorafenib tosylate may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , daunorubicin hydrochloride cytarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving sorafenib tosylate combination chemotherapy may effective treatment AML .</brief_summary>
	<brief_title>Sorafenib Tosylate Chemotherapy Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine 1-year overall survival rate patient age &gt; = 60 fms-related tyrosine kinase 3 ( FLT3 ) -internal-tandem duplication ( ITD ) AML treat sorafenib ( sorafenib tosylate ) contain induction post-remission therapy significantly high historical 1-year overall survival rate similar patient treat sorafenib . SECONDARY OBJECTIVES : I . To determine rate complete remission ( CR ) , CR incomplete count recovery ( CRi ) , cytogenetic complete remission ( CCyR ) induction chemotherapy . II . To determine overall survival , event-free survival , remission duration patient treat study . III . To describe frequency severity adverse event patient treat study . IV . To describe interaction pre-treatment disease patient characteristic include morphology , cytogenetics , immunophenotype , molecular genetic feature , white blood cell ( WBC ) count hemogram , performance status clinical outcome . V. To assess FLT3 ligand concentration FLT3 plasma inhibitory activity treatment determine relationship clinical outcome . VI . To describe interaction FLT3 mutation type ( tyrosine kinase domain [ TKD ] vs. ITD ) allelic ratio clinical outcome . VII . To characterize geriatric assessment measure context treatment trial AML define : observed distribution number miss value measurement . VIII . To identify specific geriatric assessment measure independently associate overall survival ( OS ) , 30-day treatment-related mortality key quality life outcome ( number day hospitalize , number oncology clinic visit , admission nursing facility ) patient receive induction chemotherapy AML . IX . To explore impact induction chemotherapy physical , cognitive , psychosocial factor . OUTLINE : INDUCTION THERAPY : Patients receive daunorubicin hydrochloride intravenously ( IV ) day 1-3 , cytarabine IV continuously day 1-7 , sorafenib tosylate orally ( PO ) twice daily ( BID ) day 1-7 . Patients undergo bone marrow aspirate biopsy day 14 . Patients persistent disease undergo second remission induction therapy comprise daunorubicin hydrochloride IV day 1-2 , cytarabine IV continuously day 1-5 , sorafenib tosylate PO BID day 1-7 . Patients achieve complete response ( CR ) * proceed consolidation therapy . CONSOLIDATION THERAPY : Patients** receive cytarabine IV 3 hour day 1-5 sorafenib tosylate PO BID day 1-28 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . Patients continue CR proceed maintenance therapy . MAINTENANCE THERAPY : Patients receive sorafenib tosylate PO BID day 1-28 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . NOTE : *Patients achieve CR eligible hematopoietic stem cell transplant ( HSCT ) encourage enroll Cancer Leukemia Group B ( CALGB ) 100103 . Patients CR unable unwilling undergo HSCT receive two course remission consolidation therapy . NOTE : ** Patients CR/complete remission incomplete count recovery ( CRi ) unable unwilling complete remission consolidation therapy may proceed directly maintenance therapy consult CALGB study chair . After completion study therapy , patient follow every 2 month 2 year , every 3 month 2 year , yearly maximum 10 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Unequivocal histologic diagnosis AML accord World Health Organization ( WHO ) criterion , EXCLUDING : Acute promyelocytic leukemia ( 15 ; 17 ) ( q22 ; q12 ) ; promyelocytic leukemia ( PML ) retinoic acid receptor , alpha ( RARA ) Acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 ) ; runtrelated transcription factor 1 ( RUNX1RUNXT1 ) determine Ohio State University ( OSU ) Molecular Reference Laboratory , per Cancer Leukemia Group B ( CALGB ) 20202 Acute myeloid leukemia inv ( 16 ) ( p13.1 ; q22 ) ( 16 ; 16 ( p13.1 ; q22 ) ; corebinding factor , beta subunit ( CBFB ) myosin , heavy chain 11 , smooth muscle ( MYH11 ) determine OSU Molecular Reference Laboratory , per CALGB 20202 AML patient antecedent hematologic disorder eligible treatment trial provide received chemotherapy , include lenalidomide , azacitidine decitabine hematologic disorder Patients therapyrelated AML eligible exposure chemotherapy radiation therapy &gt; 3 year primary malignancy remission FLT3 mutation ( ITD point mutation ) determine OSU Molecular Reference Laboratory , per CALGB 20202 No prior chemotherapy AML follow exception : Emergency leukapheresis Emergency treatment hyperleukocytosis hydroxyurea Cranial radiation therapy ( RT ) central nervous system ( CNS ) leukostasis ( one dose ) Growth factor/cytokine support Alltrans retinoic acid ( ATRA )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>